赛诺菲和再生元公司报告了针对IL-33通路的COPD药物的混合三期试验结果Sanofi and Regeneron Report Mixed Phase 3 Results for COPD Drug Targeting IL-33 Pathway

动脉网
30 May

by Mark Chiang马克·蒋Share To分享到Sanofi and Regeneron have released findings from two Phase 3 clinical trials evaluating their experimental drug, itepekimab, for chronic obstructive pulmonary disease (...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10